Research ArticleClinical Investigations
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Shankar Vallabhajosula, Anastasia Nikolopoulou, John W. Babich, Joseph R. Osborne, Scott T. Tagawa, Irina Lipai, Lilja Solnes, Kevin P. Maresca, Thomas Armor, John L. Joyal, Robert Crummet, James B. Stubbs and Stanley J. Goldsmith
Journal of Nuclear Medicine November 2014, 55 (11) 1791-1798; DOI: https://doi.org/10.2967/jnumed.114.140426
Shankar Vallabhajosula
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Anastasia Nikolopoulou
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
John W. Babich
2Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; and
Joseph R. Osborne
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Scott T. Tagawa
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Irina Lipai
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Lilja Solnes
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Kevin P. Maresca
2Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; and
Thomas Armor
2Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; and
John L. Joyal
2Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; and
Robert Crummet
2Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; and
James B. Stubbs
3Radiation Dosimetry Systems, Inc, Alpharetta, Georgia
Stanley J. Goldsmith
1New York Presbyterian Hospital and Weill Cornell Medical College, New York, New York
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 55, Issue 11
November 1, 2014
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Shankar Vallabhajosula, Anastasia Nikolopoulou, John W. Babich, Joseph R. Osborne, Scott T. Tagawa, Irina Lipai, Lilja Solnes, Kevin P. Maresca, Thomas Armor, John L. Joyal, Robert Crummet, James B. Stubbs, Stanley J. Goldsmith
Journal of Nuclear Medicine Nov 2014, 55 (11) 1791-1798; DOI: 10.2967/jnumed.114.140426
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen: Pharmacokinetics and Biodistribution Studies in Healthy Subjects and Patients with Metastatic Prostate Cancer
Shankar Vallabhajosula, Anastasia Nikolopoulou, John W. Babich, Joseph R. Osborne, Scott T. Tagawa, Irina Lipai, Lilja Solnes, Kevin P. Maresca, Thomas Armor, John L. Joyal, Robert Crummet, James B. Stubbs, Stanley J. Goldsmith
Journal of Nuclear Medicine Nov 2014, 55 (11) 1791-1798; DOI: 10.2967/jnumed.114.140426
Jump to section
Related Articles
Cited By...
- Eligibility for 177Lu-PSMA Therapy Depends on the Choice of Companion Diagnostic Tracer: A Comparison of 68Ga-PSMA-11 and 99mTc-MIP-1404 in Metastatic Castration-Resistant Prostate Cancer
- Robot-Assisted Prostate-Specific Membrane Antigen-Radioguided Surgery in Primary Diagnosed Prostate Cancer
- Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study
- Intraindividual Comparison of 99mTc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand 99mTc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer
- Intraindividual Comparison of 18F-PSMA-1007 and 18F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging
- Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
- Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer
- The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
- Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naive and Castration-Resistant Metastatic Prostate Cancer
- 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies